Abstract It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood vessels as an eVect of VEGF inhibition in association with chemotherapeutic agents in the treatment of tumors produces a real beneWt. Literature data show that the process of normalization of the structure of tumor blood vessels is not always accompanied with a real beneWt. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery of chemotherapeutics.
Introduction
The introduction of chemotherapy in 1950-1960 has resulted in the development of curative therapeutic interventions for patients with several types of advanced solid and hematologic tumors [1] .
In 1971, Judah Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis dependent and that inhibition of angiogenesis could be therapeutic [2] . This article also introduced the term antiangiogenesis to mean the prevention of new vessel sprouts from being recruited by a tumor. In the last 35 years, it has been estimated that more than 200 companies have worked and are still working in the area of angiogenesis and several of the compounds that modulate angiogenesis are currently being evaluated in clinical trials.
It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. Bevacizumab is a humanized monoclonal antibody that neutralizes one of the biological active forms of VEGF, VEGF-A. It appears that bevacizumab can be a component of an eVective combination therapy approach to colorectal cancer, non-small-cell-lung cancer (NSCLC), and breast cancer [3] [4] [5] . Encouraging results have also been obtained when chemotherapy has been used in combination with an anti-VEGF receptor-2 (VEGFR-2) monoclonal antibody (cediranib) [6] and an oral tyrosine kinase inhibitor of VEGFRs and epidermal growth factor receptor (EGFR) (vandetanib) [7, 8] . The observation that combining chemotherapy with angiogenesis inhibitors causes increased apoptosis in tumors in vivo [9, 10] suggests that angiogenesis inhibitors may have an additive eVect when administered in combination with chemotherapy.
The aim of this review article is to analyze whether the so-called vascular normalization of abnormal tumor blood vessels as an eVect of VEGF inhibition, generally used in association with conventional chemotherapeutic agents in the treatment of tumors, produces a real beneWt.
display the recognizable features of arterioles, capillaries, or venules [11] . Tumor-associated endothelium is structurally defective: intercellular gaps, transendothelial holes, vesiculo-vacuolar organelles, and endothelial fenestrae are present in the endothelium of tumor vessels [12] .
Defects in endothelial cell barrier function, due to abnormal cell-cell junctions and other changes, are responsible of vascular leakiness, which has been attributed also to highly active angiogenesis and microvascular remodeling. Leakiness correlates with histological grade and malignant potential [13] and can be exploited in locating tumors by imaging contrast media and in the delivery of macromolecular therapeutics [14] . Furthermore, it results in extravasation of plasma proteins and even erythrocytes and may facilitate the traYc of tumor cells into the bloodstream and the formation of metastases [13] .
Whereas endothelial cells of mature, quiescent vessels are characteristically low proliferative and their estimated turnover times are measured in years, those of tumor vessels are markedly dependent on growth factors for survival. VEGF plays a central role in the induction of host vessels into a growing tumor. When endothelial cells invade a newly formed tumor, they come into contact with tumor cells that produce VEGF, which may be responsible not only for vascular proliferation but also for the altered permeability of the newly formed vessels [15, 16] . Although tumor cells represent the major source of VEGF, tumor-associated stroma is also an important site of VEGF production [17] .
The concept of "normalization" and the role of VEGF inhibition
Excess production of pro-angiogenic factors and/or diminished production of antiangiogenic molecules may be considered responsible of the vascular structure anomalies in tumors [18] . Restore of this balance may induce a normalization of structure of blood vessels. The concept of "normalization" of tumor blood vessels by antiangiogenic drugs was introduced by Rakesh Jain in 2001 [19] . The state of normalization is probably transient and dependent on the dose and duration of the treatment.
VEGF inhibition could temporarily restore or normalize the function of tumor-associated vasculature, decreasing vascular permeability in conjunction with restoration of sustained pressure gradients, as demonstrated by intravital imaging studies in preclinical models and in cancer patients [20] , thereby enhancing systemic delivery of oxygen or perfusion of cytotoxic agents to intratumoral sites [21, 22] . Moreover, abrogation of VEGF signaling increases collagenase IV activity, leading to restoration of normal basement membrane [23] , which generally in tumors has an abnormally thickness [24] .
Temporal vascular normalization induces vascular regression, which causes tumor hypoxia [25] . Hypoxia could alter the property of cancer cells through the induction of hypoxia-inducible factor-1 (HIF-1), as HIF-1 is reported to be involved in the induction of genes that induce invasive and metastatic properties of tumor cells [26] . Hypoxia generated by angiogenesis inhibition triggers pathways that make tumors more aggressive and metastatic and less sensitive to antiangiogenic treatment, as demonstrated by Paez-Ribes et al. [27] , who used blocking VEGFR-2 antibodies to mouse models of pancreatic neuroendocrine carcinoma and glioblastoma, and found that cancers showed heightened invasiveness or metastasis.
Vascular normalization increases pericyte coverage
Pericytes of tumor vessels have an abnormally loose association with endothelial cells and have an irregular shape and cytoplasmic projections into the tumor parenchyma [28] . Irregularities in their coverage correlate with increased vascular permeability and less eVective vascular delivery [29] .
Pericytes are believed to protect the remaining vessels and defend against the anti-VEGF treatment [30] . Blockade of VEGFR-2 has been shown to increase total pericyte vasculature. In fact, blockade of VEGF signaling promotes pericyte recruitment in Lewis lung carcinomas, RIP-Tag-2 tumors [31] , and other tumor models [21, 32] , by triggering increased tumor production of angiopoietin-1 (Ang-1) [23] . Surviving blood vessels of RIP-Tag-2 tumors treated with anti-VEGF agents have a reduced expression of VEGFR-2 and VEGFR-3 in addition to a more normal caliber [29] . More recently, Helfrich et al. [33] demonstrated in spontaneously developing melanomas of MT/ret transgenic mice after using anti-VEGF therapy and in human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment with bevacizumab that tumor vessels that are resistant to anti-VEGF therapy are characterized by enhanced vessel diameter and normalization of the vascular bed by coverage of mature pericytes.
The controversial eVect of vascular normalization in the treatment of cerebral tumors
Bevacizumab is currently involved in a broad development program with more than 100 ongoing clinical trials in various indications and has been approved by the Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma [34] . Bevacizumab prolongs progression-free survival and controls peritumoral edema, but its eVects on overall survival remain to be determined. The decrease in brain edema due to vascular normalization is thought to be an important factor of its beneWt [35] .
Other inhibitors of VEGF, VEGFRs, and other proangiogenic signaling pathways are being evaluated. MRI scans showed that treatment with cediranib (AZ 2171), a small molecule inhibitor of VEGFRs, lowered blood vessel size and permeability, consistent with the hypothesis of vascular normalization [36] . Cediranib monotherapy was used in a clinical trial for recurrent glioblastoma with encouraging radiographic response and 6-month progression-free survival [37] . Sorensen et al. [38] evaluated after a single dose of cediranib the correlation between clinical outcome in glioblastoma patients and MRI changes in vascular permeability/Xow and in microvessel outcome and the change of circulating collagen IV levels. They demonstrated that the changes in these parameters and their combination in a "vascular normalization index" correlate with duration of overall survival and/or progression-free survival.
The inhibitors of VEGF in the therapy of central nervous system malignancy normalize tumor vasculature and decrease tumor interstitial pressure, leading to an improved access of cytoreductive drugs and radiotherapy eYcacy, due to an increased oxygen delivery [39] . However, these agents may also restore the low permeability characteristics of normal brain microvasculature, counteracting beneWcial eVects. The presence of an intact blood-brain barrier in some areas of the tumor and the presence of a partially functional blood-brain barrier in other areas of the tumor can prevent the delivery of therapeutic compounds.
The interplay between the eVects of VEGF inhibition and angiopoietins in normalization VEGFR-2 blockade can lead to the upregulation of Ang-1 that increase pericyte coverage of the vessels [23] . Ang-2 plays a more important role in tumor angiogenesis than it does in normal angiogenesis. As an antagonist for Ang-1, it is responsible for blood vessel destabilization in vasculature surrounding tumors.
In glioblastoma patients, the Ang-1/Ang-2 ratio correlates with survival [40] and vascular normalization [37] , whereas high Ang-2 levels correlate with resistance to anti-VEGF therapy [37] . Moreover, blockade of VEGF signaling with the VEGFR tyrosine kinase inhibitor cediranib signiWcantly reduced levels of Ang-2 in some patients, even if the decrease was transient and modest [37] .
Chae et al. [41] in an orthotopic glioma model demonstrated that ectopic expression of Ang-2 had no eVect on vascular permeability, tumor growth, or survival, but it resulted in higher vascular density, with dilated vessels and reduced mural cell coverage. When combined with anti-VEGFR-2 treatment, Ang-2 destabilized vessels and compromised the survival beneWt of VEGFR-2 inhibition by increasing vascular permeability, suggesting that VEGFR-2 inhibition normalized tumor vasculature, whereas ectopic expression of Ang-2 diminished the beneWcial eVects of VEGFR-2 blockade by inhibiting vessel normalization.
Concluding remarks
A number of studies have demonstrated the validity and clinical beneWt of inhibiting angiogenesis in various types of cancer. However, as it has been clariWed in this article, it should be considered that the process of normalization of the structure of tumor blood vessels as a consequence of the use of anti-VEGF antibodies is not always accompanied with a real beneWt. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery of chemotherapeutics.
